Health and Fitness Health and Fitness
Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010
Wed, July 21, 2010
Tue, July 20, 2010
[ Tue, Jul 20th 2010 ] - Market Wire
00 AM EDT
Mon, July 19, 2010
Sun, July 18, 2010
Sat, July 17, 2010
Fri, July 16, 2010
Thu, July 15, 2010
Wed, July 14, 2010
Tue, July 13, 2010
Mon, July 12, 2010
Fri, July 9, 2010
Thu, July 8, 2010
Wed, July 7, 2010
Tue, July 6, 2010
Mon, July 5, 2010
Fri, July 2, 2010
[ Fri, Jul 02nd 2010 ] - Market Wire
Celgene????Abraxis BioScience??

Furiex Pharmaceuticals Announces Second Quarter 2010 Earnings Release and Conference Call


//health-fitness.news-articles.net/content/2010/ .. r-2010-earnings-release-and-conference-call.html
Published in Health and Fitness on Wednesday, July 14th 2010 at 13:35 GMT by Market Wire   Print publication without navigation


MORRISVILLE, N.C.--([ BUSINESS WIRE ])--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its second quarter 2010 financial results on Wednesday, August 11, 2010, after the market closes. The earnings news release will be available on the Furiex website at [ www.furiex.com ].

On Thursday, August 12, 2010, at 9 a.m. ET, Furiex will conduct a live conference call and audio webcast to discuss financial results and product portfolio. A Q&A session will follow. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:

Participant dial-in: +1 866 735 8913 (U.S./Canada)
+1 706 643 0961 (International)
Conference ID: 87379426

All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at [ www.furiex.com ]. The webcast will be archived shortly after the call for on-demand replay.

About Furiex Pharmaceuticals

Furiex Pharmaceuticals is a drug development collaboration company using innovative clinical development design to accelerate and increase value of partnered drug programs by advancing them through the drug discovery and development process in a cost-efficient manner. Development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets and one product on the market. The companya™s mission is to develop innovative medicines faster and at less cost, reducing the expense of health care globally while providing life-improving therapies for patients. For more information, visit [ www.furiex.com ].


Publication Contributing Sources